The angiotensin-converting enzyme (ACE) I/D polymorphism is an insertion/deletion of an ALU-repeat sequence of 287 base pairs (bp) in intron 16 of the ACE gene, located at 17q23. This results in three genotypes: II, ID and DD, with individuals with the DD genotype having about 40-50% higher circulating plasma ACE levels than individuals with the II genotype and individuals with the ID genotype having intermediate levels [1, 2] .
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ACE plays a role in platelet activation and aggregation and a reduced fibrinolysis [3] . Increased ACE levels could therefore theoretically lead to an increased risk of thrombosis, a hypothesis which is supported by the finding that ACEinhibitors have an antithrombotic effect in rat models [4] .
Several studies have focused on the relationship between the DD genotype and the occurrence of thrombosis. In individuals following total hip arthroplasty, Philipp et al. found a considerably increased risk of thrombotic events for individuals carrying the DD genotype compared with individuals carrying the II genotype [odds ratio (OR) 11.7, 95% confidence interval (CI): 2.3-84.5] [5] . Subsequent studies yielded conflicting results, with some reporting an increased risk of thrombosis for individuals with the DD genotype [6] [7] [8] [9] , and others not finding any association between the I/D polymorphism and thrombosis [10] [11] [12] [13] .
We investigated the relationship between this polymorphism and deep venous thrombosis (DVT) in a large casecontrol study, the Leiden Thrombophilia Study (LETS), which has been described in detail elsewhere [14] . In short, 474 patients with an objectively confirmed first episode of DVT from three Dutch anticoagulation centers and 474 age-and sex-matched control subjects from the same geographic area were enrolled. Subjects with a known malignant disorder were excluded. The ACE I/D genotype is determined by polymerase chain reaction, as also described by Rigat et al. [15] . Results were obtained for 471 cases and 472 control subjects (see Table 1 ).
Genotypes of controls were in Hardy-Weinberg equilibrium (v 2 ¼ 0.006, P ¼ 0.94); the frequency of the D-allele among controls was 0.51, which is consistent with frequencies reported in other Caucasian populations [16] . The risk estimates, i.e. OR and 95% CI of the different genotypes, are summarized in Table 1 .
Contrary to expectations we found a slight protective effect of the D-allele with regard to deep venous thrombosis (OR DD vs. II: 0.7, 95% CI 0.5-1.0). When the subjects were stratified by sex, it became clear that the low overall risk for the D allele was due almost entirely to a reduced risk in women (DD vs. II women OR: 0.5, 95% CI: 0.3-0.9; men OR: 0.9, 95% CI 0.5-1.6). In men, no protective effect of the D-allele was found regardless of age, but the overall protective effect in women in our study was found to be restricted to women younger than 50 years of age (DD vs. II women < 50 years OR: 0.4, 95% CI: 0.2-0.7; women > 50 years OR: 1.1, 95% CI: 0.4-2.7). Adjustment for age and several other possible thrombophilic traits (use of an oral contraceptive, pre/postmenopausal status) did not affect these results.
Gonzalez Ordonez et al. found a protective effect of the D allele in Spanish men [11] . Recently, Wells et al. also reported a protective effect on the risk of venous thrombosis associated with the D allele, although not significant after restricting to patients with a first venous thrombotic event [17] . In the latter study, the protective effect seemed more pronounced in men than in women, although subgroups were small. Even though our result is statistically significant at the 5% level, the upper limit of the 95% CI approaches 1.0, and thus a type I error could be the cause, in particular as a protective effect is difficult to explain. There are several possible explanations for the diverse results on the association between the I/D genotype and the risk of thrombosis. Firstly, the studies varied widely in the types of patients investigated, e.g. surgery patients [5, 10] , pregnant women [6] . Secondly, inclusion criteria differed as to whether only patients with a first event of thrombosis were included (current study) or patients with a history of thrombosis.
In addition, the studies with smaller numbers of participants tend to report higher odds ratios than the larger studies. This could suggest publication bias, but it could also be that in the specific subgroups investigated in the smaller studies (postoperative subjects, African-Americans, pregnant women) carrying the D allele does indeed result in a higher risk of developing thrombosis than it does in the larger samples of unselected patients.
Ethnic background may also play a role. The smaller studies reporting a high relative risk mainly originated from the United States (sometimes including only, or many African-Americans), while larger studies mainly originate from Europe or Canada. Differences could be due to chance fluctuation, but perhaps differences in gene-gene and environment-gene interactions play a role.
There is increasing evidence that the I/D polymorphism is not the functional polymorphism determining ACE levels, but that it is in LD with a functional variant located more to the 3¢ region of the ACE gene [18] [19] [20] [21] . In conclusion, the results of this study provide insufficient evidence of an association between the ACE I/D polymorphism and the risk of deep venous thrombosis.
